Epstein-Barr Virus Infections: Clinical Trials

1,148 trials for Epstein-Barr Virus Infections, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

573 completed, 158 recruiting, 145 terminated, 112 unknown. 496 Phase 1, 479 Phase 2, 89 Phase 3, 78 Not applicable, 32 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 1496Completed 237, Terminated 69, Recruiting 68, Unknown 46, Active not recruiting 31, Withdrawn 24, Not yet recruiting 17, Suspended 3, Enrolling by invitation 1
Phase 2479Completed 236, Terminated 65, Recruiting 60, Unknown 41, Withdrawn 33, Active not recruiting 29, Not yet recruiting 12, Suspended 2, Enrolling by invitation 1
Phase 389Completed 46, Recruiting 15, Unknown 13, Terminated 8, Active not recruiting 6, Not yet recruiting 1
Not applicable78Completed 42, Terminated 15, Recruiting 13, Withdrawn 5, Unknown 2, Not yet recruiting 1
Early Phase 132Unknown 13, Not yet recruiting 6, Recruiting 6, Completed 4, Terminated 2, Withdrawn 1
Phase 49Recruiting 3, Completed 2, Unknown 2, Terminated 1, Withdrawn 1

Follow Epstein-Barr Virus Infections: new trials by email Literature Review of Epstein-Barr Virus Infections trials Research Report on Epstein-Barr Virus Infections

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma
Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
Phase 2 / Phase 3RecruitingNational Cancer Institute (NCI)2712027-07-272026-11-17
Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma
Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma
Phase 1RecruitingCity of Hope Medical Center162027-04-172026-11-13
Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI.
CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies
Phase 1Not yet recruitingGUSTAVO SALGUERO122027-04-012026-10-20
Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)
Asciminib, Inotuzumab ozogamicin - B-cell Acute Lymphoblastic Leukemia (B-ALL)
Phase 1RecruitingSunil G. Iyer452027-03-312026-11-13
Metabolically Fit CD19 CAR T Cells With CD34 Selection Markers in Adults With CD19-Positive B-Cell Acute Lymphocytic Leukemia
Fludarabine, Cyclophosphamide, Levetiracetam - CD19 Positive, B-ALL
Phase 1Not yet recruitingMedical University of South Carolina182027-02-012026-11-13
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Burkitt Lymphoma, Double-Expressor Lymphoma
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)502027-01-112026-10-14
Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome
Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia
Phase 2Not yet recruitingFred Hutchinson Cancer Center522027-01-012026-09-14
Study Of KITE-753 in R/R B-Cell ALL
KITE-753 - B-cell Acute Lymphoblastic Leukemia
Phase 1Not yet recruitingM.D. Anderson Cancer Center182026-12-312026-09-11
Phase 1 Trial to Evaluate Safety and Immunogenicity of MVA-BN-EBV in Healthy Young Adults
MVA-BN-EBV, Placebo - Epstein Barr Virus (EBV) Infection
Phase 1Not yet recruitingBavarian Nordic152026-12-152026-10-22
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Phase 1 / Phase 2Not yet recruitingBeOne Medicines302026-12-012026-10-26
Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia
Rituximab - PTLD, Epstein Barr Virus (EBV) Infection
Phase 1Not yet recruitingJennifer Amengual282026-12-012026-09-17
CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study
MB-CART19.1 - Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Phase 1 / Phase 2Not yet recruitingHospital Universitario Dr. Jose E. Gonzalez302026-12-012026-10-22
BLinatumomab and iNKT in Relapsed B-Cell ALL
Invariant Natural Killer T Cell Therapy - B-Cell ALL, ALL (Acute B-Lymphoblastic Leukemia)
Phase 1Not yet recruitingUNC Lineberger Comprehensive Cancer Center132026-12-012026-11-05
A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia
Blinatumomab Injection - B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult
Phase 1 / Phase 2Not yet recruitingMemorial Sloan Kettering Cancer Center262026-12-012026-11-09
mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults
VXCO-102, Placebo - EBV
Phase 1RecruitingVaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company822026-11-162026-10-26
EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases
Donor-derived ex-vivo expanded EBV Tscm CTL - EBV Lymphoma, Post-transplant Lymphoproliferative Disease (PTLD)
Phase 1 / Phase 2Not yet recruitingUniversity Hospital, Basel, Switzerland102026-11-012025-03-03
25BT056: Basket Study of Viral Cytotoxic T Lymphocytes
Virus-Specific Cytotoxic T Lymphocytes (vCTLs) - EBV Viremia, CMV Viremia
Early Phase 1Not yet recruitingChildren's Hospital of Philadelphia352026-11-012026-10-22
Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment
Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
Phase 2Not yet recruitingSWOG Cancer Research Network902026-10-142026-10-13
Pre-emptive Anakinra for Cytokine Event Reduction
Anakinra (Kineret®) - B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy
Phase 1 / Phase 2WithdrawnKevin McNerney2026-10-012026-08-13
Epstein-Barr Virus Antibodies in Egyptian Patients With Multiple Sclerosis
Multiple Sclerosis, Epstein-Barr Virus Infections
Not yet recruitingAssiut University1402026-10-012026-09-29

Showing 20 of 1148. Sign in to see all of them.

Narrower conditions

Burkitt Lymphoma (977)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (585)  ·  Lymphoma, Large B-Cell, Diffuse (574)  ·  Lymphoma, Follicular (522)  ·  Lymphoma, Mantle-Cell (508)  ·  Lymphoma, Non-Hodgkin (502)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (464)  ·  Lymphoma, B-Cell, Marginal Zone (458)  ·  Lymphoma (447)  ·  Lymphoma, Large-Cell, Immunoblastic (445)  ·  Hodgkin Disease (351)  ·  Leukemia (267)  ·  Leukemia, Myeloid, Acute (252)  ·  Lymphoma, T-Cell, Cutaneous (252)  ·  Multiple Myeloma (248)

Broader conditions

DNA Virus Infections (1148)  ·  Herpesviridae Infections (1145)  ·  Tumor Virus Infections (1142)  ·  Virus Diseases (1136)  ·  Infections (1111)  ·  Immune System Diseases (1039)  ·  Hemic and Lymphatic Diseases (1027)  ·  Lymphatic Diseases (1024)  ·  Neoplasms by Histologic Type (1022)  ·  Immunoproliferative Disorders (1021)  ·  Lymphoproliferative Disorders (976)  ·  Neoplasms (976)  ·  Lymphoma, B-Cell (904)  ·  Hematologic Diseases (730)

Interventions

Cyclophosphamide (226)  ·  Rituximab (121)  ·  Etoposide (104)  ·  Methotrexate (95)  ·  Vincristine (95)  ·  Peripheral Blood Stem Cell Transplantation (94)  ·  Cytarabine (93)  ·  Filgrastim (92)  ·  fludarabine phosphate (85)  ·  Doxorubicin (73)  ·  Prednisone (69)  ·  Radiotherapy (67)  ·  Dexamethasone (62)  ·  Cyclosporine (53)  ·  Mycophenolic Acid (53)

Sponsors

National Cancer Institute (NCI) (117)  ·  Fred Hutchinson Cancer Center (59)  ·  M.D. Anderson Cancer Center (34)  ·  City of Hope Medical Center (28)  ·  Memorial Sloan Kettering Cancer Center (27)  ·  Children's Oncology Group (25)  ·  Masonic Cancer Center, University of Minnesota (25)  ·  Case Comprehensive Cancer Center (22)  ·  Roswell Park Cancer Institute (16)  ·  Mayo Clinic (15)  ·  National Institutes of Health Clinical Center (CC) (15)  ·  Medical College of Wisconsin (14)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (14)  ·  Alliance for Clinical Trials in Oncology (13)  ·  Baylor College of Medicine (13)

Countries

United States (800)  ·  China (133)  ·  Canada (75)  ·  France (56)  ·  Italy (48)  ·  Germany (44)  ·  United Kingdom (44)  ·  Australia (38)  ·  Spain (31)  ·  Puerto Rico (27)  ·  Switzerland (26)  ·  Belgium (24)  ·  Netherlands (23)  ·  South Korea (20)  ·  Israel (15)

Top investigators

Ajay Gopal (9)  ·  Elias Jabbour (7)  ·  Helen E Heslop, MD (6)  ·  Philip L. McCarthy, MD (6)  ·  Christos E. Emmanouilides, MD (5)  ·  David Maloney (5)  ·  Elias Jabbour, MD (5)  ·  Ibrahim Aldoss (5)  ·  Roger Strair, MD, PhD (5)  ·  Brenda Sandmaier (4)  ·  Christopher J Melani, M.D. (4)  ·  Claudio G. Brunstein, MD, PhD (4)  ·  Ephraim J. Fuchs, MD (4)  ·  Helen Heslop, MD (4)

Results publications

PMID 41671463, PMID 35622074, PMID 34515338, PMID 32499241, PMID 32589970, PMID 38551807, PMID 17242396, PMID 19949018, PMID 20028764, PMID 21527516, PMID 22002018, PMID 22337718, PMID 24862638, PMID 33308471, PMID 33496754, PMID 34353848, PMID 34432863, PMID 34473237, PMID 34687939, PMID 34806163, PMID 34889384, PMID 35422096, PMID 35489026, PMID 35732829, PMID 36736781, PMID 37486616, PMID 37890117, PMID 39121442, PMID 40367950, PMID 41774854, PMID 42341322, PMID 10552943, PMID 10632319, PMID 10764422, PMID 10820362, PMID 11410496, PMID 11600602, PMID 11756154, PMID 12121233, PMID 12171484, PMID 12525530, PMID 1403051, PMID 14508361, PMID 14630685, PMID 14767498, PMID 15013589, PMID 15042678, PMID 15107815, PMID 15459300, PMID 15466923

NIH funding

P30CA033572 (24), P30CA015704 (19), P30CA043703 (17), U10CA032102 (15), P30CA006973 (13), P30CA015083 (12), U10CA180886 (12), P30CA022453 (11), P30CA072720 (9), U01CA097452 (9), U10CA098543 (9), P30CA016672 (8), 2023 (7), P30CA068485 (7), U10CA031946 (7)